Oximetry reveals abnormal oxygen metabolism in exudative AMD


Professor Stef?nsson reveals the results of a comparative study demonstrating that observation of metabolic processes is possible enabling insight into the pathophysiology of disease.

The design of the non-invasive retinal oximeter is based on a fundus camera. It simultaneously captures images of the retina at 600 nm and 570 nm and estimates retinal vessel oxygen saturation, then producing an image in which the degrees of oxygen saturation are indicated by different colours.

To establish whether the retina metabolises oxygen differently in an eye with AMD than in a healthy eye, the Oximetry Group in Reykjavik, including Asbjorg Geirsdottir, Sveinn Hakon Hardarson and professor Einar Stefánsson (University of Iceland, National University Hospital, Reykjavik, Iceland) compared the oximetry images of healthy eyes with those of eyes with exudative AMD.

When oxygen saturation in AMD patients is compared with healthy individuals a statistically significant difference is seen. While the venous oxygen saturation of healthy individuals decreases with age, in AMD patients the opposite pattern is seen.

He continued, "The preliminary results indicate that oxygen metabolism is different in healthy and AMD eyes."

Related Videos
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Giulia Corradetti, MD, discusses her presentation "Functional Microperimetric Correlates of OCT Structures Features in Intermediate AMD"
At this year's ARVO meeting, Paolo Silva, MD, presented data on Protocol AA on behalf of the DRCR Retina Network
Baruch Kuppermann, MD, PhD
At this year's ARVO meeting, Qinqin Zhang, PhD, presented a poster titled "A unified deep learning model for geographic atrophy segmentation: Adaptable to SS-OCT and SD-OCT data with multiple scan patterns."
Ash Abbey, MD, shares 36-month data from the GALE study of pegcetacoplan
© 2024 MJH Life Sciences

All rights reserved.